Key Highlights
- Oxford BioDynamics Plc (LSE:OBD) gained 5.71% on 7 October 2026.
- The company signed its first commercial agreement for the EpiSwitch Orion 3D genomics platform in July 2026.
- EpiSwitch PSE prostate cancer test sales have passed 5,000 tests since launch, with a US sales Partnership aimed at accelerating growth.
- Chief Executive Richard Compton joined the Board in August 2026 and owns about 2.2% of the company.
Oxford BioDynamics Shares Advance on 7 October 2026
Oxford BioDynamics Plc (LSE:OBD), the Oxford-based biotechnology company developing precision clinical diagnostics, rose 5.71% on 7 October 2026. The AIM-quoted company, a member of the FTSE AIM All-Share Index, uses its proprietary EpiSwitch 3D genomic platform to create blood tests and analytical tools for diseases including cancer.
The shares have been under pressure for a long period as the company worked through funding challenges and cost reductions. Recent commercial milestones, however, have given investors reasons to revisit the story.
Why Oxford BioDynamics Shares Rose 5.71%
No new company announcement had been confirmed as the direct trigger for the move at the time of writing. The rise appears to reflect ongoing interest in the commercialisation of EpiSwitch Orion and the company's prostate cancer test, combined with speculative buying in a very low-priced stock.
The first commercial agreement for EpiSwitch Orion, announced on 28 July 2026, was an important step. It showed that pharmaceutical partners are willing to pay for the platform, which converts standard sequencing data, including legacy whole genome datasets, into actionable discovery insights in hours rather than months.
The company also said in June that it was in commercial discussions with three large pharmaceutical companies about Orion, leaving room for further agreements.
The EpiSwitch Product Portfolio
Oxford BioDynamics currently has two commercially available tests. EpiSwitch PSE is a blood test that assesses the likelihood of prostate cancer and aims to reduce unnecessary biopsies. EpiSwitch CiRT is a test designed to predict a patient's response to immune checkpoint inhibitor cancer therapies.
EpiSwitch PSE sales have surpassed 5,000 tests since launch. A new agreement with US third-party sales organisation MK Commercial Group is expected to increase the company's US field presence by about 60%, which could speed up adoption.
EpiSwitch Orion, launched in March 2026, is a cloud-based platform for pharmaceutical and biotech partners and has been introduced into several research centres of excellence.
ME/CFS Opportunity
The company's EpiSwitch data in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) has attracted interest from industry and academia. Oxford BioDynamics is seeking non-dilutive or grant funding for this initiative and aims to launch a credible ME/CFS test, which would be a first-in-class product.
Leadership and Financial Position
On 27 August 2026, Chief Executive Richard Compton was appointed to the Board as an Executive Director. He owns 300 million shares, about 2.2% of the company, aligning his interests with those of shareholders.
In its interim results published on 30 June 2026, the company reported a lower operating loss of £4.68 million, compared with £5.88 million a year earlier, helped by higher Revenue and lower research and staff costs. Securing near-term funding remains a primary consideration for management, with partnering, licensing and direct Investment among the Options under review.
Why Investors Are Watching LSE:OBD
Oxford BioDynamics is in focus because it is at an early commercial stage across three opportunities: a growing prostate cancer test, a pharmaceutical data platform and a potential ME/CFS test. Investors are watching for further Orion agreements, US PSE test volumes, any licensing deals for CiRT or other tests, and the company's funding plans.
Risks to Consider
Oxford BioDynamics remains loss-making and needs further funding, which could lead to substantial dilution. Adoption of new diagnostic tests can be slow, and reimbursement is not assured. CiRT promotion is limited until it gains inclusion in clinical guidelines. The share price is very low, and AIM biotech stocks can be extremely volatile.
Outlook
The 5.71% gain on 7 October 2026 reflects renewed interest in Oxford BioDynamics as it builds commercial traction for its EpiSwitch platform. With a first Orion agreement in place, rising PSE test sales and a CEO with a meaningful shareholding, LSE:OBD has several catalysts in motion. Securing funding on acceptable terms will be the key issue for the shares in the months ahead.






Please wait processing your request...